Clinical Trial Information

Tanabe Pharma Corporation (herein after Tanabe Pharma) has been working to improve transparency about clinical trial information. For more details, please click here to see our Clinical Trial Information Disclosure Policy.

This page provides patients, healthcare professionals, researchers, and others with information about our company clinical trials, the status of registration on each public registry, clinical trial results and publications, data sharing with researchers, and links to each registry.

Please note that the status of registration on public registries are available in the "List of Summaries of Clinical Trial Information" on the Tanabe Pharma Clinical Trial Information Site.

In order to provide information on clinical trials to patients, healthcare professionals, researchers, and others, Tanabe Pharma posts clinical trial information on public registries. The registries provide clinical trial information such as a summary of the clinical trials, the target diseases, and the status of the clinical trials.

For more information, please visit the Tanabe Pharma Clinical Trial Information Site.

Tanabe Pharma is committed to disclose clinical trial results that are available to patients, healthcare professionals, researchers, and others. Tanabe Pharma is also preparing to disclose a summary of results that are easy to understand for patients and the public.

Tanabe Pharma will endeavor to provide relevant presentations at scientific meetings, or publications in scientific journals of the clinical trial results where results are considered of significant medical importance at an appropriate time. When such an article is published, Tanabe Pharma will post the place of publication on public registries.

For more information, please visit the Tanabe Pharma Clinical Trial Information Site.

When requested by a qualified researcher in the field of science or medicine, Tanabe Pharma will share clinical trial data that was collected from individual patients in a clinical trial with that researcher after a review committee of experts determines that such sharing is appropriate. Such clinical data will always be anonymized before sharing. Tanabe Pharma will not share data that Tanabe Pharma feels may place the patient at risk of being identified.

Tanabe Pharma will share patient data from clinical trials in patients that form part of the submission package for products and indications approved in all regions of the US, Europe and Japan where approval is sought, in and after January 2018.